🔗 Permalink

Inventor profile of:

Ronald Levy

City:

Stanford, California

Country:

United States

Published Applications:

Last publication date:

2025-12-18

Top Assignees for applications by Ronald Levy

The entities that hold a legal rights for patent applications filed by inventor Levy Ronald:

The Board of Trustees of the Leland Stanford Junior University 11 Stanford, CA United States
The Board of Trustees of the Leland Stanford Junior University 2 Palo Alto, CA United States
LIFE TECHNOLOGIES CORPORATION 1 Carlsbad, CA United States

Recent patent applications by Levy Ronald

Ronald Levy from Stanford, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-12-18

US20250381276A1

Human necessities

SMALL MOLECULE CONJUGATED CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY

#2 | 2025-06-05

US20250177559A1

Human necessities

BRANCHED LIPID CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY

#3 | 2024-08-22

US20240277854A1

Human necessities

IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY TO THE LUNG

#4 | 2024-05-09

US20240148858A1

Human necessities

A THREE COMPONENT VACCINE FOR COVID-19

#5 | 2022-08-18

US20220257785A1

Human necessities

KNOTTIN-IMMUNOSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS

#6 | 2020-12-24

US20200397895A1

Human necessities

TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY

#7 | 2020-01-16

US20200017915A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR DETERMINING RESPONSIVENESS TO ANTIBODY THERAPY

#8 | 2019-06-13

US20190177425A1

Chemistry; metallurgy

Humanized and chimeric monoclonal antibodies to CD81

#9 | 2018-07-26

US20180208670A1

Chemistry; metallurgy

Methods for enhancing anti-tumor antibody therapy

#10 | 2017-02-02

US20170029524A1

Chemistry; metallurgy

Humanized and chimeric monoclonal antibodies to CD99

#11 | 2016-08-18

US20160235842A1

Human necessities

MEDICAL USES OF CD38 AGONISTS

#12 | 2016-03-24

US20160083474A1

Chemistry; metallurgy

Methods for enhancing anti-tumor antibody therapy

#13 | 2015-11-05

US20150315660A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR DETERMINING RESPONSIVENESS TO ANTIBODY THERAPY

#14 | 2015-04-30

US20150118222A1

Human necessities

TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY

#15 | 2014-08-07

US20140220562A1

Chemistry; metallurgy

Method of predicting responsiveness of B cell lineage malignancies to active immunotherapy

#16 | 2012-12-20

US20120321646A1

Chemistry; metallurgy

Methods for enhancing anti-tumor antibody therapy

#17 | 2012-05-31

US20120134986A1

Human necessities

Methods of Prognosis for Non-Hodgkin Lymphoma

#18 | 2011-06-02

US20110129438A1

Chemistry; metallurgy

IMMUNOGENIC PROTEIN CONSTRUCTS

#19 | 2010-07-22

US20100183655A1

Chemistry; metallurgy

Immunogenic protein constructs

#20 | 2010-06-10

US20100143926A1

Physics

Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene Expression

#21 | 2007-02-01

US20070026453A1

Physics

Classification of patients having diffuse large b-cell lymphoma based upon gene expression

#22 | 2006-01-26

US20060018911A1

Human necessities

Design of therapeutics and therapeutics

#23 | 2006-01-12

US20060008825A1

Chemistry; metallurgy

Methods and compositions for determining responsiveness to antibody therapy

#24 | 2005-04-14

US20050079513A1

Physics

Classification of patients having diffuse large B-cell lymphoma based upon gene expression

InventorID:

863047 ⎘